Drug Profile
Rabies vaccine - YS Biopharma
Alternative Names: PIKA adjuvant-based rabies vaccine - YS Biopharma; PIKA rabies vaccine - YS BiopharmaLatest Information Update: 02 Nov 2023
Price :
$50
*
At a glance
- Originator Yisheng Biopharma
- Developer YS Biopharma
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Rabies
Most Recent Events
- 31 Oct 2023 YS Biopharma completes enrolment in its phase III trial for Rabies (Prevention) in Pakistan and Philippines (IM)
- 26 Sep 2023 Phase-III clinical trials in Rabies (Prevention) in Pakistan, Philippines (IM) (NCT05667974)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Rabies(Prevention) in China (IM, Injection)